Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Biagio De Angelis

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Nature Medicine|August 21, 2025
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trialFranco Locatelli, Daria Pagliara, Maria A De Ioris, et al.
Neuro-Oncology|December 29, 2021
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutantEmmanuel de Billy, Marsha Pellegrino, Domenico Orlando, et al.
Acta Neuropathologica|July 24, 2021
Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signallingFrancesca Nazio, Agnese Po, Luana Abballe, et al.
Cell Death Discovery|August 6, 2024
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaksMatteo Cassandri, Antonella Porrazzo, Silvia Pomella, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?Sonia Guedan, Maik Luu, Delphine Ammar, et al.
Haematologica|May 9, 2020
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cellsMarika Guercio, Domenico Orlando, Stefano Di Cecca, et al.
Journal of Hematology & Oncology|December 19, 2024
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cellsMichele Pezzella, Concetta Quintarelli, Maria C Quadraccia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ MedulloblastomaRoselia Ciccone, Concetta Quintarelli, Antonio Camera, et al.
Frontiers in Oncology|May 1, 2020
Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
Frontiers in Oncology|July 14, 2020
Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Nature Medicine|August 21, 2025
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trialFranco Locatelli, Daria Pagliara, Maria A De Ioris, et al.
Neuro-Oncology|December 29, 2021
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutantEmmanuel de Billy, Marsha Pellegrino, Domenico Orlando, et al.
Acta Neuropathologica|July 24, 2021
Targeting cancer stem cells in medulloblastoma by inhibiting AMBRA1 dual function in autophagy and STAT3 signallingFrancesca Nazio, Agnese Po, Luana Abballe, et al.
Cell Death Discovery|August 6, 2024
HDAC3 genetic and pharmacologic inhibition radiosensitizes fusion positive rhabdomyosarcoma by promoting DNA double-strand breaksMatteo Cassandri, Antonella Porrazzo, Silvia Pomella, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?Sonia Guedan, Maik Luu, Delphine Ammar, et al.
Haematologica|May 9, 2020
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cellsMarika Guercio, Domenico Orlando, Stefano Di Cecca, et al.
Journal of Hematology & Oncology|December 19, 2024
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cellsMichele Pezzella, Concetta Quintarelli, Maria C Quadraccia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ MedulloblastomaRoselia Ciccone, Concetta Quintarelli, Antonio Camera, et al.
Frontiers in Oncology|May 1, 2020
Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
Frontiers in Oncology|July 14, 2020
Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working GroupDominga Racanelli, Monica Brenca, Davide Baldazzi, et al.
Pageof 7